Introduction
Cyclin-dependent kinases (CDKs) are critical regulators of cell-cycle progression, becoming activated upon binding to cyclins. Progression through the G 1 phase of the cell cycle is mediated by activation of the CDK4/6-cyclinD complex and subsequent phosphorylation of the Retinoblastoma protein (Rb), which triggers E2F-dependent transcription 1, 2 . CDK4 and CDK6 show 71% amino acid homology and have been considered to fulfil largely redundant functions as only the simultaneous deletion of both genes leads to embryonic lethality due to hematopoietic defects 3, 4 . Cdk6-deficiency is characterized by subtle defects in the hematopoietic system, such as defects in thymocyte development and a reduction in erythrocyte numbers 4, 5 . CDK6
has been shown to have a kinase-independent function in myeloid cells, where it interacts with RUNX1 to block RUNX1-dependent transcription 6 . We recently discovered a key role for CDK6 in lymphoma formation: CDK6 transcriptionally
regulates Vegf-A and p16 INK4a by interacting with STAT and AP-1 transcription factors 7 . A subsequent report described CDK6 as a transcriptional co-regulator of NF-κB p65 8 . CDK6 appears to have a key role in hematopoietic tumors, where it is frequently up-regulated 5, 7 . CDK6 has also been shown to be critical in AML and ALL driven by MLL fusion proteins 9, 10 . There is considerable interest in targeting CDK4/6
in cancer therapy and the FDA nominated CDK4/6 inhibitors as the "breakthrough therapeutic advance" in 2013.
All hematopoietic cells arise from hematopoietic stem cells (HSCs), which possess the ability to self-renew and to differentiate into all blood cell lineages 11 . The There is evidence that LSCs may remain dormant for a very long period (up to ten years) 22 , explaining the high rate of relapse of leukemia patients after extended periods of remission. LSCs thus remain a major therapeutic challenge.
We describe a new facet of the regulation of HSCs and LSCs. Cdk6-deficient HSCs lack the ability to repopulate in competitive transplant experiments and fail to respond adequately to challenge with polyinosinic:polycytidylic acid (poly(I:C)) and 5-FU.
Furthermore, Cdk6 -/-BCR-ABL p210+ LSCs fail to repopulate upon transplantation.
These results identify CDK6 as a crucial player in HSC/LSC activation. Committee at the Veterinary University of Vienna.
Cell-cycle analysis
Cell-cycle analysis was performed in a two-step protocol by staining with antibodies directed against HSC surface markers followed by intracellular staining with Ki-67 (BD Bioscience) and DAPI. For intracellular staining, cells were fixed in Cytofix/Cytoperm (BD Biosciences), washed and stained with Ki-67 FITC (BD Bioscience) followed by co-staining with 0.1mg/100ml DAPI in PBS with 0.1% Triton X-100 (Sigma).
Transplantation studies
For competitive transplantion assays, BMs of Cdk6
mice were mixed at a ratio of 1:9, 1:1 or 9:1 and injected intravenously into lethally irradiated (9 Gy) C57Bl/6J mice (in total 5x10 6 cells/mouse (Fig 1E) .
Cdk6 -/-mice harbor increased levels of quiescent HSCs
Under homeostatic conditions, the numbers of cells in the BM of Cdk6 -/-animals were comparable to those of controls ( Fig S2A) 4 and the total LSK numbers were unaltered (Fig S2B) . Examination of individual LSK subpopulations using SLAM (Fig S2C) .
Under homeostatic conditions, the majority of cells in fraction A are in the G 0 phase 12 and we failed to detect any significant differences in the cell-cycle profile of Cdk6
and Cdk6 -/-fraction A (Fig 2D) , fraction B or fraction C cells (Fig S2D) . Furthermore, we observed no significant differences in numbers of apoptotic cells in LSK and fraction A cells between genotypes (Fig S2E) .
Enhanced lethality of Cdk6 -/-mice upon repeated 5-FU treatment
The chemotherapeutic drug 5-FU kills dividing cells but spares dormant HSCs, which are subsequently forced to proliferate to repopulate the BM 29 . Cdk6 -/-mice tolerated only two cycles of 5-FU application. In contrast, only 1 out of 5 Cdk6 +/+ mice succumbed to repeated 5-FU treatment within 65 days, with the remainder surviving until the experiment was terminated after 150 days (Fig 3A and Fig 3B) . After a single dose of 5-FU, the percentage of cells in fraction A (which includes the most quiescent stem cells) was significantly enhanced in Cdk6 -/-animals within 8 days ( Fig   3C) . More of the cells in fraction A from the Cdk6 -/-mice remained in the G 0 phase (Fig 3D) , indicative of their reduced ability to exit quiescence. No significant alterations in proportion of cells in the G 0 phase were detectable in cells in fractions B
and C (Fig S3A) . (Fig S4A and Fig S4B) . No alterations in the cell cycle distribution of fraction B or C cells were detected (Fig S4C) .
Exit from quiescence is controlled by a network of transcriptional regulators including
Nurr1, Egr1, Runx1 and p21
CIP1
. Poly(I:C) treatment induced Cdk6 expression by about 3-fold in cells of fraction A, whereas the level of Cdk4 mRNA remained pro-B cells (Fig S6D) and in Cdk6 -/-LSKs transduced with Cdk6, Cdk6 K43M or empty vector control (Fig 4F and Fig S6E) . Table S1 and Table S2 ). Gene ontology analysis suggested that the deregulated genes are involved in a variety of biological processes as summarized in Table 1 .
CDK6 is part of a transcription factor network that regulates stem cell quiescence
The majority of the known regulators of stem cell quiescence were not significantly affected although there were significant changes to the levels of Nurr1, Atm, Hoxc4
and (especially) Egr1 ( Table 2 ). The outcome of a JASPAR-TFB screen for targets of specific transcription factors is summarized in Fig 5B. We found levels of Nurr1 target genes (see Table S3 ) to be significantly affected by the loss of CDK6 in unstimulated cells. In contrast, the key transcription factors with different activities in Fig S7) . In summary, the findings indicate that the CDK6-Egr1 axis represents an important part of a transcription factor network that controls exit from quiescence of hematopoietic stem cells. leukemic cells succumbed to leukemia (Fig 6C) . Mice that received BCR-ABL p210+
Cdk6
-/-cells remained disease-free for up to 60 days. Analysis of the mice confirmed that Cdk6 -/-LSCs had homed efficiently to the BM. Despite their presence, no signs of leukemia could be detected in the recipient animals (Fig 6D and Fig 6E) . BCR-ABL p210+ LSCs derived from Cdk6 +/+ and Cdk6 -/-mice express identical surface markers, which are reminiscent of those on fraction C cells (Fig S8A) . When we analyzed the cell cycle of the remaining Cdk6 +/+ and Cdk6 -/-BCR-ABL p210+ LSKs we again found more Cdk6 -/-BCR-ABL p210+ LSKs in the G 0 phase (Fig S8B) .
Egr1 knock-down rescues colony formation in Cdk6 -/-BCR-ABL p210+ LSCs
In vitro colony formation assay (CFA) confirmed the in vivo observation. After 48h coculture of BM cells on retroviral producers, BCR-ABL p210+ LSKs were sorted and either seeded at three different cell numbers in methylcellulose to assess their (re- (Fig 7A) . Eight days after plating we observed a profound reduction of Cdk6 -/-leukemic clones, irrespective of the number of cells initially plated (Fig 7B and Fig 7C) . (Fig 7E) . To assess the functional relevance we performed shRNA-mediated knockdowns for Egr1, validating the constructs in a hematopoietic cell line (BCR-ABL p185+ pro B cells) (Fig S9A) before introducing them into Cdk6 -/-BCR-ABL p210+ LSKs. Colony formation assays revealed a highly significant increase in growth factor-independent colony numbers (Fig 7F and Fig 7G) and thus confirmed the importance of the CDK6/Egr1 axis in BCR-ABL p210+ mediated leukemogenesis.
For Maintaining the balance between proliferation and differentiation is not only important in recovery from hematopoietic stress; it is also a central issue in leukemia patients 22, 51 . HSCs play a crucial part in malignancies such as chronic myeloid leukemia (CML), which is reflected by the fact that only the transplantation of transformed HSCs is able to induce murine BCR-ABL p210+ -driven myeloid leukemia.
In CML, quiescent LSCs represent the leukemic stem cell compartment and are protected from conventional chemotherapy and tyrosine kinase inhibitors, allowing them to survive for many years and posing a significant challenge to therapeutic attempts 52, 53 . Imatinib represented a major breakthrough in therapy, although it only targets the peripheral symptoms of leukemia. The idea of inhibiting CDK6 may seem provocative but our data show that it warrants further investigation. It may be beneficial to develop inhibitors that specifically target CDK6's ability to regulate transcription. CDK4 and CDK6 are clearly non-redundant with regard to arousing d- and P 24130-B20).
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Bar graphs depict Egr1 mRNA expression levels (technical triplicates; *: p < 0.05, **: p < 0.01). 
